Perspectum promotes liver biomarker's performance in study

By staff writers

March 25, 2022 -- Perspectum has highlighted its LiverMultiScan biomarker's performance in improving autoimmune hepatitis management, after the results of a study were published on 21 March in the Lancet.

The LiverMultiScan-cT1 is an MRI-derived noninvasive tissue biomarker that the company said identifies patients in biochemical remission and patients in deep remission with undetected, active subclinical disease at a high risk of disease relapse.

The study was led by researchers from Kings College Hospital and Oxford University Hospitals. Perspectum said it showed that cT1 measurements obtained with the LiverMultiScan outperformed blood biomarkers and FibroScan in identifying patients likely to experience disease progression, despite being in biochemical remission.

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking